Current Oncology, Volume 21, Issue 6

Objective: The objective of the present analysis was to determine the publicly funded health care costs associated with the care of breast cancer (BCa) patients by disease stage. Methods: Incident cases of female invasive BCa (2005–2009) were extract...

Background: Cervical cancer (cca) is largely a preventable disease if women receive regular screening, which allows for the detection and treatment of preinvasive lesions before they become invasive. Having been inadequately screened is a common find...

Background: Activating mutations of the epidermal growth factor receptor (EGFR) gene are known to drive a proportion of non-small-cell lung cancers. Identification of lung cancers harbouring such mutations can lead to effective treatment using one of...

Molecular strategies to improve outcomes for patients with pancreatic neuroendocrine tumours (nets) have focused on targeting vascular endothelial growth factor, platelet-derived growth factor, and mtor (the mammalian target of rapamycin). This appro...

Background: Before the emergence of first-line combination chemotherapy, the standard of care for unresectable metastatic colorectal cancer (mCRC) was first-line monotherapy with modulated 5-fluorouracil. Several large phase III randomized controlled...

Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) erlotinib and gefitinib were developed to target the epidermal growth factor...

Positron-emission tomography (pet) has emerged as an effective imaging method for diagnosing, staging, [...]

Purpose: We investigated correlations of somatic BRAF V600E mutation and RET/PTC1 rearrangement with recurrent disease in Chinese patients with papillary thyroid carcinoma (PTC). Methods: This prospective study included 214 patients with PTC histolog...

(1) Background: In the phase iii palette trial of pazopanib compared with placebo in patients with advanced or metastatic soft-tissue sarcoma (sts) who had received prior chemotherapy, pazopanib treatment was associated with improved progression-free...

Purpose: We evaluated the novel combination of aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting (RINV) among patients receiving moderately-emetogenic radiotherapy for thoracolumbar bone metastases. Methods: I...

Background: Combined positron-emission tomography and computed tomography (PET-CT) reduces futile thoracotomy (FT) rates in patients with non-small-cell lung cancer (NSCLC). We sought to identify preoperative risk factors for FT in patients staged wi...

Follicular dendritic cell sarcoma (FDCS) is a rare entity, often presenting a diagnostic challenge for both the pathologist and the clinician. It accounts for only 0.4% of soft-tissue sarcomas, and its underlying causes are largely unknown. Most of t...

Glioblastoma is the most common form of primary brain cancer. Its treatment involves surgery, radiotherapy, and chemotherapy with temozolomide (TMZ), which is an oral alkylating agent. To the best of our knowledge, few dermatologic side effects of TM...

Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patien...

Background: Children with high-grade glioma still have a poor prognosis despite the use of multimodal therapy including surgery, radiotherapy, and chemotherapy. New therapeutic strategies and methods evaluating such therapies are needed. Observation:...

The second Systemic Treatment Safety Symposium, which took place February 21, 2014, in Toronto, aimed to identify opportunities for improving the delivery of systemic cancer treatment in Ontario based on regional needs, while providing a venue for co...

Sanford et al. reported results from an interviewassisted survey of chronic myeloid leukemia (CML) patients, which indicated that neither treatment compliance nor the occurrence of side effects significantly affected patient willingness to stop tyros...

We thank Villemagne et al. for their comments, and we will address some of the issues that they raised.[...]

In the first paragraph of the article, the author mentions that “Pamela Fayerman received a grant of $20,000 from the Canadian Institutes of Health Research in 2012 to pursue health journalism research” as part of his introduction to the hypotheses o...